Amgen Buys Alantos Pharmaceuticals

Thousand Oaks-based Amgen has made yet another acquisition this week, saying Wednesday that it has acquired Alantos, a company developing drugs for the treatment of diabetes and inflammatory disease. The deal is worth $300M in cash, and is expected to close in Q3 of 2007. Alantos has locations in Cambridge, Massachusetts and Heidelberg Germany, and employs 45. Alantos is venture backed by Oxford Bioscience Partners, SV Life Sciences, Earlybird, Forbion Capital Partners, Heidelberg Innovation, and Ventech.